Aclarubicin: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{SI}} {{CMG}} {{SK}} Aclacinomycin A ==Overview== Aclarubicin is an anthracycline drug <ref name="pmid1655244">{{cite journal| author=Jensen PB, Jensen PS, Demant...")
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477240878
| IUPAC_name = (1''S'',2''S'',4''R'')-Methyl 4-(((2''S'',5''R'',6''R'')-4-(dimethylamino)-5-(((1''S'',3''R'',4''S'')-3-hydroxy-5-methyl-4-(((2''S'',6''R'')-6-methyl-5-oxotetrahydro-2''H''-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2''H''-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
| image = Aclarubicin.png
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|aclarubicin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 57576-44-0
| ATC_prefix = L01
| ATC_suffix = DB04
| ATC_supplemental = 
| PubChem = 42474
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1931
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 74KXF8I502
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02756
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 74619
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1697719
<!--Chemical data-->
| C=42 | H=53 | N=1 | O=15
| molecular_weight = 811.86 g/mol
| smiles = CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
| InChI = 1/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3
| InChIKey = USZYSDMBJDPRIF-UHFFFAOYAH
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = USZYSDMBJDPRIF-UHFFFAOYSA-N
}}
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}
==Overview==
'''Aclarubicin''' ([[International Nonproprietary Name|INN]]) or '''aclacinomycin A'''<ref name="pubchem">{{PubChem|451415}}</ref> is an [[anthracycline]] drug<ref name="pmid1655244">{{cite journal |author=Jensen PB, Jensen PS, Demant EJ, ''et al.'' |title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II |journal=Cancer Res. |volume=51 |issue=19 |pages=5093–9 |date=October 1991 |pmid=1655244 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1655244}}</ref> that is used in the treatment of [[cancer]]. Soil bacteria ''[[Streptomyces galilaeus]]'' can produce aclarubicin.


{{SK}} Aclacinomycin A
==References==
{{reflist|2}}


==Overview==
{{Chemotherapeutic agents}}
Aclarubicin is an anthracycline drug <ref name="pmid1655244">{{cite journal| author=Jensen PB, Jensen PS, Demant EJ, Friche E, Sørensen BS, Sehested M et al.| title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. | journal=Cancer Res | year= 1991 | volume= 51 | issue= 19 | pages= 5093-9 | pmid=1655244 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1655244  }} </ref> that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.


==References==
[[Category:Anthracyclines]]
{{Reflist|2}}
[[Category:Topoisomerase inhibitors]]


{{WH}}
{{WS}}


[[Category:Needs content]]
{{antineoplastic-drug-stub}}

Latest revision as of 19:23, 6 April 2015

Aclarubicin
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC42H53NO15
Molar mass811.86 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Aclarubicin

Articles

Most recent articles on Aclarubicin

Most cited articles on Aclarubicin

Review articles on Aclarubicin

Articles on Aclarubicin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aclarubicin

Images of Aclarubicin

Photos of Aclarubicin

Podcasts & MP3s on Aclarubicin

Videos on Aclarubicin

Evidence Based Medicine

Cochrane Collaboration on Aclarubicin

Bandolier on Aclarubicin

TRIP on Aclarubicin

Clinical Trials

Ongoing Trials on Aclarubicin at Clinical Trials.gov

Trial results on Aclarubicin

Clinical Trials on Aclarubicin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aclarubicin

NICE Guidance on Aclarubicin

NHS PRODIGY Guidance

FDA on Aclarubicin

CDC on Aclarubicin

Books

Books on Aclarubicin

News

Aclarubicin in the news

Be alerted to news on Aclarubicin

News trends on Aclarubicin

Commentary

Blogs on Aclarubicin

Definitions

Definitions of Aclarubicin

Patient Resources / Community

Patient resources on Aclarubicin

Discussion groups on Aclarubicin

Patient Handouts on Aclarubicin

Directions to Hospitals Treating Aclarubicin

Risk calculators and risk factors for Aclarubicin

Healthcare Provider Resources

Symptoms of Aclarubicin

Causes & Risk Factors for Aclarubicin

Diagnostic studies for Aclarubicin

Treatment of Aclarubicin

Continuing Medical Education (CME)

CME Programs on Aclarubicin

International

Aclarubicin en Espanol

Aclarubicin en Francais

Business

Aclarubicin in the Marketplace

Patents on Aclarubicin

Experimental / Informatics

List of terms related to Aclarubicin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.

References

  1. Template:PubChem
  2. Jensen PB, Jensen PS, Demant EJ; et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244.


Template:Antineoplastic-drug-stub